Lymphoma of the Skin

+ -Text Size

Other Resources and References TOPICS

References: Lymphoma of the skin detailed guide

Akilov OE, Geskin L. Therapeutic advances in cutaneous T-cell lymphoma. Skin Therapy Lett. 2011;16:1-5.

American Cancer Society. Cancer Facts & Figures 2014. Atlanta, Ga: American Cancer Society; 2014.

Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma incidence patterns in the United States: A population-based study of 3884 cases. Blood. 2009;113:5064-5073.

Foss FM, Edelson RL, Wilson LD. Cutaneous lymphomas. In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2011:1894-1907.

Galper SL, Smith BD, Wilson LD. Diagnosis and management of mycosis fungoides. Oncology. 2010;24:491-501.

Haberman TM, Pittelkow MR. Cutaneous T-cell lymphoma and cutaneous B-cell lymphoma. In: Abeloff MD, Armitage JO, Niederhuber JE. Kastan MB, McKenna WG, eds. Abeloff’s Clinical Oncology. 4th ed. Philadelphia, Pa: Elsevier; 2008:2405-2424.

Hymes KB. Cutaneous T-cell lymphoma: Mycosis fungoides and Sezary syndrome. In: Rigel DS, Friedman RJ, Dzubow LM, Reintgen DS, Bystryn JC, Marks R, eds. Cancer of the Skin. Philadelphia, Pa: Elsevier Saunders; 2005:349-362.

Lansigan F, Foss FM. Management of cutaneous T-cell lymphoma. Clinical Oncology News Special Edition. 2009;12:59-67.

Lansigan F, Foss FM. Updates in the diagnosis and treatment of mycosis fungoides and Sezary syndrome. Clinical Oncology News Special Edition. 2010;13:75-79.

National Cancer Institute Physician data Query (PDQ): Mycosis Fungoides and the Sezary Syndrome Treatment. 2012. Accessed at www.cancer.gov/cancertopics/pdq/treatment/mycosisfungoides/HealthProfessional on December 15, 2012.

National Comprehensive Cancer Network (NCCN). Practice Guidelines in Oncology: Non-Hodgkin’s Lymphomas. Version 3.2012. Accessed at: www.nccn.org/professionals/physician_gls/pdf/nhl.pdf on December 15, 2012.

Kim YH, Willemze R, Pimpinelli N, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: A proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110:479-484.

Lundin J, Hagberg H, Repp R, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood. 2003;101:4267-4272.

Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: Vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007;12:1247-1252.

Molina A, Zain J, Arber DA, et al. Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides. J Clin Oncol. 2005;23:6163-6171.

Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110:1713-1722.

Prince HM, Whittaker S, Hoppe RT. How I treat mycosis fungoides and Sezary syndrome. Blood. 2009;114:4337-4353.

Senff NJ, Noordijk EM, Kim YH, et al. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood. 2008;112:1600-1609.


Last Medical Review: 03/14/2013
Last Revised: 02/11/2014